Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
529.8 INR | +0.69% | +1.94% | +4.16% |
05-14 | Transcript : Jubilant Ingrevia Limited, Q4 2024 Earnings Call, May 14, 2024 | |
05-14 | Jubilant Ingrevia Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.82 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.16% | 1.01B | B | ||
+2.92% | 49.79B | A- | ||
+19.98% | 42.5B | B+ | ||
+22.29% | 26.45B | A- | ||
+12.04% | 19.66B | C+ | ||
+0.75% | 17.18B | B+ | ||
-24.51% | 15.82B | A- | ||
+3.42% | 15.56B | B+ | ||
-9.92% | 15.41B | C+ | ||
-18.80% | 13.67B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JUBLINGREA Stock
- Ratings Jubilant Ingrevia Limited